Suppr超能文献

加拿大确诊白血病或淋巴瘤的儿童和青少年治疗启动延迟的决定因素。

Determinants of delays in treatment initiation in children and adolescents diagnosed with leukemia or lymphoma in Canada.

机构信息

Department of Oncology, McGill University, Montreal, Canada.

Department of Epidemiology, McGill University, Montreal, Canada.

出版信息

Int J Cancer. 2010 Apr 15;126(8):1936-1943. doi: 10.1002/ijc.24906.

Abstract

Minimizing delays that may occur along the cancer care pathway requires an understanding of their determinants. Few studies on childhood cancers have been published on the factors that influence the time it takes for patients to get a first medical consultation (patient delay) and treatment (health care system [HCS] delay) once cancer symptoms have been recognized. Our objective was to assess factors related to disease, patient and HCS on patient and HCS delay for children and adolescents with leukemias and lymphomas in Canada. A prospective cohort study was conducted on subjects enrolled in the Treatment and Outcomes Surveillance program of the Canadian Childhood Cancer Surveillance and Control Program, a national surveillance program. We studied 963 leukemia and 397 lymphoma patients who were less than 19-years old at diagnosis in 1995-2000. Logistic regression models were used to measure the associations between candidate predictive factors and delays. Age was positively associated with patient delay for both leukemia and lymphoma patients, but not with HCS delay. Patients first seen in a hospital emergency room had a lower risk of HCS delay than patients first seen by a general practitioner. Cancer subtype was associated with patient delay for leukemia patients, and HCS delay for lymphoma patients. Longer patient delay was associated with a lower risk of long HCS delay for both cancers. Factors related to the patients, their disease and the HCS may exert different influences on varying segments of the care pathway of leukemia and lymphoma patients.

摘要

减少癌症治疗路径中可能出现的延误需要了解其决定因素。关于影响癌症症状出现后患者首次就诊(患者延误)和接受治疗(医疗保健系统[HCS]延误)时间的因素,针对儿童癌症的研究很少。我们的目的是评估与疾病、患者和 HCS 相关的因素对加拿大儿童白血病和淋巴瘤患者的患者延误和 HCS 延误的影响。在加拿大儿童癌症监测和控制计划的治疗和结果监测计划中,对 1995-2000 年期间诊断时未满 19 岁的 963 例白血病和 397 例淋巴瘤患者进行了前瞻性队列研究。该计划是一个全国性监测项目。我们研究了年龄小于 19 岁的 963 例白血病和 397 例淋巴瘤患者,他们在 1995-2000 年期间被诊断为白血病和淋巴瘤。使用逻辑回归模型来衡量候选预测因素与延误之间的关联。年龄与白血病和淋巴瘤患者的患者延误呈正相关,但与 HCS 延误无关。先在医院急诊室就诊的患者比先在全科医生处就诊的患者发生 HCS 延误的风险较低。癌症亚型与白血病患者的患者延误有关,与淋巴瘤患者的 HCS 延误有关。对于两种癌症,较长的患者延误与 HCS 延误较长的风险较低相关。与患者、疾病和 HCS 相关的因素可能对白血病和淋巴瘤患者的治疗路径的不同阶段产生不同的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验